Citations

Clear

2960 citation(s) found for "Kim, P".

In Children, N-Methyl-D-Aspartate Receptor Antibody Encephalitis Incidence Exceeds That of Japanese Encephalitis in Vietnam
Hương, Nguyễn Hoàng Thiên , Toan, Nguyen Duc , Thien, T , Khanh, Truong Huu, Tuan, Nguyen Minh, Nguyen, Nghia An , Thinh, Le Quoc, Thoa, Nguyen Thi Kim, Nhan, Le Nguyen Thanh, Minh, Ngo Ngọc Quang, Thwaites, Louise , Hùng, Nguyễn Thanh , Irani, Sarosh R. , Quy, Dư Tuấn, Thien, Tran Ba , Nghia, Nguyen An , Turner, Hugo C , Thwaites, C Louise , Hung, Nguyen Thanh , Tan, Le Van , Irani, Sarosh R , Tuan, Nguyen Minh, Truc, Tran Thanh

Mayo Clinic

Open Forum Infectious Diseases | November 28, 2024 | Volume: 11 | Issue: 12 | Pages: No page available

10.1093/ofid/ofae710 | PMID 39691294 Get It

Abstract Background The recognition of autoimmune causes of encephalitis has led to epidemiological shifts in the worldwide characteristics of encephalitis. N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis leads to well-established complex neuropsychiatric manifestations. In low- and middle-income countries, including Vietnam, its relative incidence, especially in children, is unknown and most neurologists currently consider infectious encephalitis prior to autoimmune etiologies. Methods The study was prospectively conducted at Children's Hospital 1 in Ho Chi Minh City between March 2020 and December 2022. Any child admitted to the Department of Infectious Diseases and Neurology fulfilling the case definition of encephalitis was eligible to participate. Cerebrospinal fluid samples were collected alongside meta-clinical data for analysis. Results We recruited 164 children with a clinical diagnosis of encephalitis. Etiologies were determined as NMDAR antibody encephalitis in 23 of 164 cases (14.0%), Japanese encephalitis virus in 14 of 164 (8.5%), and herpes simplex virus in 4 of 164 (2.4%). Clinical categorizations suggested idiopathic viral encephalitis in another 71 (43.3%), and autoimmune encephalitis of unknown origin in the remaining 52. Factors including demographics, specific clinical features, cerebrospinal fluid and electroencephalogram findings, and length of hospital stay were significantly different between NMDAR antibody encephalitis and Japanese encephalitis. Conclusions At a tertiary children's hospital in Vietnam, the prevalence of NMDAR antibody encephalitis exceeds that of Japanese encephalitis, the most common infectious encephalitis cause in Southeast Asia. NMDAR antibody encephalitis is associated with long hospital stay and poor outcomes. These findings should change pediatric diagnostics, to earlier consider autoimmune treatments in this clinical setting.
Contrast Media in Children: Ten Important Concepts on Administration, Applications, Complications, and Environmental Considerations, From the AJR Special Series on Contrast Media
Forbes-Amrhein, Monica M., Chow, Jeanne S. , Kim, Helen H. R. , Krishnamurthy, Rajesh , McDonald, R.J. , Scheller, Leah G., Stein, Deborah R., Callahan, Michael J. , Horst, Kelly K. , Maloney, Ezekiel J. , Gilligan, Leah A.

Mayo Clinic

American Journal of Roentgenology | November 27, 2024 | Volume: 225 | Issue: 4 | Pages: No page available

10.2214/ajr.24.32009 | PMID 39602099 Get It

Genomic Reporting Practices Across 5 Molecular Disciplines: A Study From the College of American Pathologists
Furtado, Larissa V. , Moyer, Ann M. , Moncur, Joel T., Xian, Rena R. , Roy, Angshumoy , Santani, Avni , Akkari, Yassmine, Voelkerding, Karl V., Souers, Rhona J., Halley, Jaimie , Kim, Annette S , Richards, C. Sue

Mayo Clinic

Archives of Pathology & Laboratory Medicine | November 22, 2024 | Volume: 149 | Issue: 7 | Pages: 627-634

10.5858/arpa.2024-0207-cp | PMID 39576195 Get It

Context.— Genomic reports are primarily organized in a narrative and unstructured format with variations in content and format. Regulatory requirements and professional guidelines for genetic test reporting exist but provide little guidance for effective communication of information. Objective.— To assess clinical genomic reporting practices across 5 disciplines within molecular diagnostics, including germline, somatic solid tumors, somatic hematologic malignancies, pharmacogenomics, and prenatal cell-free DNA screening. Design.— Reporting practices were assessed by using a structured review of clinical genomic reports from multiple laboratories in 5 molecular disciplines spanning different practice settings. Report content was reviewed by the presence/absence of from 27 to 44 elements, including 23 elements required by the College of American Pathologists and/or the Clinical Laboratory Improvement Amendments of 1988 (CLIA). If present, the element’s location on the report was recorded. Results.— A total of 69 genomics reports from 31 laboratories were reviewed. Overall, the reports were compliant with regulatory requirements but showed variability in both format and content. Six of 7 required reporting elements (per CLIA, 42 CFR [Code of Federal Regulations] 493.1291) were included in 90% of the reports. However, these elements were often located in different report sections. Only patient demographics were always found in a specific report section (header). Conclusions.— These results show that reports are overall compliant with regulatory requirements, despite some reporting elements being less consistently reported. The lack of consistent presentation of the data elements presents an opportunity to improve the communication of molecular testing results to clinicians and patients.
A Cost of Illness Analysis of Children with Encephalitis Presenting to a Major Hospital in Vietnam
Hương, Nguyễn Hoàng Thiên , Toan, Nguyen Duc , Khanh, Truong Huu, Thinh, Le Quoc, Nhan, Le Nguyen Thanh, Minh, Ngo Ngọc Quang, Thoa, Nguyen Thi Kim, Hùng, Nguyễn Thanh , Quy, Dư Tuấn, Thwaites, Louise , Irani, Sarosh R. , Irani, Sarosh R , Thwaites, C Louise , Tan, Le Van , Turner, Hugo C

Mayo Clinic

The American Journal of Tropical Medicine and Hygiene | November 19, 2024 | Volume: 112 | Issue: 2 | Pages: 422-430

10.4269/ajtmh.24-0409 | PMID 39561390 Get It

ABSTRACT. Encephalitis is a significant global health problem, especially in children. Knowledge of its economic burden is essential for policymakers in prioritizing the development and implementation of interventions but remains limited. An observational study was prospectively conducted at a major children’s hospital in Ho Chi Minh City, Vietnam from 2020 to 2022. Data on direct medical costs, direct nonmedical costs, and productivity costs were collected alongside demographic information, clinical features, diagnosis, severity, and outcomes of study participants. This was used to undertake a cost of illness analysis from a societal perspective. Data were collected from a total of 164 pediatric patients. The median cost of illness was estimated at US $1,859 (interquartile range [IQR]: US $1,273–$3,128). The direct costs were the main cost driver, accounting for 83.9% of the total cost of illness (US $1,560; IQR: US $975–$2,460). The productivity costs accounted for a median of US $275 (IQR: US $154–$474). The cost of illness was higher in more severe patients, patients with sequelae, patients with morbidities, and ventilated patients. Most direct medical costs were attributed to hospitalization and resulted in out-of-pocket payments from the patient’s family (30.2%; US $316). The results showed that the cost of illness of encephalitis in children is considerable and will be useful for policymakers in prioritizing resources for the development and implementation of intervention strategies to reduce the burden of pediatric encephalitis.
Pharmacist Medication Titration Program for Patients With Cardiac Sarcoidosis and Systolic Heart Failure: A Retrospective Cohort Study
Sykora, Daniel , Olson, Nicole, Kim, B Michelle , Bratcher, Melanie, Elwazir, Mohamed Y. , Young, Kathleen A. , Ryan, Sami, Brodin, Michelle, Anderson, Jan, Saunders, Jeremiah, Ezzeddine, Omar Abou, Bois, John P. , Giudicessi, John R. , Rosenbaum, Andrew , AbouEzzeddine, Omar F. , Churchill, Robert , Elwazir, Mohamed , Young, Kathleen , Abou Ezzeddine, Omar, Giudicessi, J R , Cooper, Leslie T , Rosenbaum, Andrew N , AbouEzzeddine, Omar F , Kim, B Michelle , Cooper, Leslie T.

Mayo Clinic

Journal of the American Heart Association | November 18, 2024 | Volume: 13 | Issue: 24 | Pages: No page available

10.1161/jaha.124.038965 | PMID 39556701 Get It

Background A multidisciplinary approach improves guideline‐directed medical therapy in systolic heart failure (HF), but its efficacy in patients with HF due to cardiac sarcoidosis is unreported. Methods and Results In a retrospective cohort study, we reviewed 848 patients from our institutional cardiac sarcoidosis clinics, identifying those with a cardiac sarcoidosis diagnosis, HF (left ventricular ejection fraction <50%) at index evaluation, and echocardiograms within 90 days and 11 to 36 months. Patients were stratified by participation in a pharmacist‐led medication therapy management (MTM) program for guideline‐directed medical therapy optimization (MTM versus non‐MTM [NMTM]) without randomization. Demographics, left ventricular ejection fraction, guideline‐directed medical therapy (quantified by Kansas City Medical Optimization score), and immunosuppressive therapy were assessed. Primary outcomes included changes in Kansas City Medical Optimization score, left ventricular ejection fraction, and cardiovascular event–free survival (unplanned HF hospitalization, left ventricular assist device /heart transplant, or death). The final cohort included 111 patients (median age, 57 years; 34% women; 64% New York Heart Association class I–II); 43 (39%) were MTM and 68 (61%) were NMTM. Mean Kansas City Medical Optimization score was similar at index evaluation (MTM, 23.2; NMTM, 29.6; P =0.83). At follow‐up (median, 16 months), the Kansas City Medical Optimization score increased significantly in both groups (MTM, 23.2 to 74.8; P <0.001; NMTM, 29.6 to 58.7; P <0.001) but was higher in MTM ( P =0.001). Mean left ventricular ejection fraction trended toward higher values in MTM (44.4% versus 40.0%, P =0.05). The primary clinical outcome occurred in 1 MTM (2.3%) and 16 NMTM (23.5%) patients, with higher risk in NMTM (hazard ratio, 11.97 [95% CI, 1.58–90.54]; P =0.002). Conclusions In this retrospective cohort study, a pharmacist‐led MTM program was associated with favorable guideline‐directed medical therapy optimization and lower risk of adverse cardiovascular outcomes in patients with cardiac sarcoidosis with HF.
Orofacial Granulomatosis and Crohn's Disease: A Case Series
Urquhart, Siri A. , Kim, Grace Y. , Anderson, Katelyn , Anderson, Katelyn R, Chedid, Victor G , Chedid, Victor

Mayo Clinic

ACG Case Reports Journal | November 16, 2024 | Volume: 11 | Issue: 11 | Pages: e01559

10.14309/crj.0000000000001559 | PMID 39559789 Get It

ABSTRACT Orofacial granulomatosis (OFG) is a rare syndrome that can occur in association with Crohn's disease (CD). The electronic medical record was searched for “OFG” and “CD.” A total of 297 patients were identified, and relevant data were abstracted. Five patients met inclusion criteria. Most (80%) had ileocolonic CD with nonstricturing/nonpenetrating phenotype. The most common treatments included intralesional corticosteroids (4 patients), oral corticosteroids (3 patients), and anti-TNF agents, specifically infliximab (3 patients). Intralesional corticosteroid administration was followed by partial response in 3 patients, but recurrences were common following initial injection. One patient had no response to topical or oral corticosteroids, antihistamines, or oral antibiotics, but partial response to intralesional corticosteroids and infliximab. None of the patients had complete response to any therapies directed at this condition. OFG may be characterized by partial response, often requiring long-term therapy. Additional investigations into novel treatments may improve future clinical outcomes.
Surgeon preferences for self-treatment in locally advanced non–small cell lung cancer: Would we practice what we preach?
Brunelli, Alessandro , Petersen, René Horsleben , Stiles, Brendon M. , Wigle, Dennis A. , Collaborators, Platz, Joseph , Muesse, Jason , Grenda, Tyler R., Makey, Ian A. , Khandhar, Sandeep J. , Schipper, Paul H., Linsky, Paul L., Liptay, Michael J, Pechet, Taine, White, Abby , Wood, Douglas E. , Brandt, Whitney S. , Martin, Linda D., Patterson, Alec, Seder, Christopher W. , Lanita, Michael, Molena, Daniela , Lee, Jay M. , Healy, David , Decker, G. Anton , Sihoe, Alan , Zairi, Sarra , Dunning, Joel , Raveglia, Federico , Kleontas, Athanasios, Szántó, Zalán , Nosotti, Mario , Hudson, Jessica , Schneiter, Didier, Asadi, Nizar , Aranda, J.M. Botía, Congregado, Miguel , Backhus, Leah, Bertani, Alessandro , Nadal, Sergio Bolufer, Rosso, Lorenzo, Gattás, Gustavo, Augustin, Florian , Milton, Richard , Vannucci, Fernando , Waller, David , Gasparri, Mario, Reddy, Rishindra M. , Schreurs, W. H. , Saftić, Igor, Scarci, Marco, Toker, Seyfi Alper, Welcker, K , Furák, József, Durand, Marion, Hugen, Niek , Joseph, Lula Lukadi, Chiappetta, Marco , Pérez, María Rodríguez, Minasyan, Anna , Filose, Pier Luigi, Elkhayat, Hussein , Wei, Benjamin , Leone, Richard J., Chang, Albert S., Curcio, Carlo, Sparks, Preston, Hagen, Jeffrey A., Baste, Jean Marc , Taylor, Lauren , Xavier, D'journo, Hall, David Jeffrey, Hansen, Henrik Jessen, Leschber, Gunda, Koryllos, Aris , Gandhi, Shilpa , Batgirl, Hasan, Calvin, Ng Sze Hang, Sotiropoulos, Georgios C. , Furrer, Markus , Danjouma, Cheufou, Novoa, Nuria , Cassivi, Stephen D. , Veronesi, Giulia , Hamouri, Shadi , Štupnik, Tomaž , Hall, David J. , Antonoff, Mara B. , Collaborators, Louie, Brian E. , Daddi, Niccolò , Swisher, Stephen G. , Yendamuri, Sai S , Liptay, Michael J, Herrera, Luis, Martin, Linda, Patterson, Alec, Sandri, Alberto , Ruffini, Enrico , Maurizi, Giulio , Kleontas, Athanasios, Depypere, Lieven , Caruana, Edward Joseph , Mitchell, John , Gonfiotti, Alessandro , Pagès, P , Aranda, Jose, Billè, Andrea , Falcoz, Pierre‐Emmanuel , Rosso, Lorenzo , Terra, Ricardo Mingarini , Raemdonck, Dirk Van , Minervini, Fabrizio , Tosi, Davide , Solli, Piergiorgio , Scarci, Marco , Gooseman, Michael , Gossot, Dominique , Álvarez, Antonio , Toker, Seyfi Alper, Aramini, Beatrice , Guerrera, Francesco , Jiménez, Marcelo Fernando , Bölükbas, Servet , Thomas, P. A. , Luzzi, Luca , Aigner, Clemens , Minasyan, Anna, Kim, Young Tae , Pompili, Cecilia , Shargall, Yaron , Fiorelli, Alfonso , Curcio, Carlo, Bilfinger, Thomas V. , Engelhardt, Kathryn Elizabeth , Hall, David Jeffrey, Akopov, Andrey L. , Loos, Erik Robert de , Karamustafaoğlu, Yekta Altemur , Bertolaccini, Luca , Hendriks, Jeroen M. , Scanagatta, Paolo , Prisciandaro, Elena , Gómez-Hernández, María Teresa , Agrafiotis, Apostolos C. , Casiraghi, Monica , Danjouma, Cheufou Housmanou, Mariani, Alessandro Wasum , Antonio, David Gómez de , Bolca, Ciprian Nicolae , Cattaneo, Margherita

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | November 15, 2024 | Volume: 66 | Issue: 5 | Pages: No page available

10.1093/ejcts/ezae344 | PMID 39545513 Get It

Multi‐Functional Biomaterial for the Treatment and Prevention of Central Line‐Associated Bloodstream Infections (Adv. Mater. 46/2024)
Albadawi, Hassan , Çevik, Enes , Kim, Jinjoo , Keum, Hyeongseop , Zhang, Zefu , Graf, Erin H. , Öklü, Rahmi

Mayo Clinic

Advanced Materials | November 15, 2024 | Volume: 36 | Issue: 46 | Pages: No page available

10.1002/adma.202470365 Get It

Abstract 4143175: Real-world Long-term Effectiveness of Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: a Multicenter Observational Study (MARVEL-HCM)
Abraham, Theodore P. , Martinez, Matthew N., Roehl, Kaitlin , Patel, Ruchi , Herry, Morgane , Wang, Manchen Annie, Schuler, Patricia , Dubey, Anand Prakash , Alsidawi, Said , Martinez, Matthew, Wheeler, Matthew T , Soutar, Marybeth, Kim, Mi‐Ok , Dubey, Anand

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4143175 Get It

Background: Mavacamten was approved by the US Food and Drug Administration (FDA) in April 2022 for the treatment of adults with New York Heart Association (NYHA) class II-III symptomatic obstructive hypertrophic cardiomyopathy (HCM). Few studies have reported on the long-term real-world effectiveness and safety of mavacamten. We evaluated clinical outcomes in patients on mavacamten in multiple health centers across the United States. Research Questions: This study assessed the real-world effectiveness and safety of mavacamten in patients with symptomatic obstructive HCM. Methods: In this multi-center observational study, we evaluated patient characteristics at baseline, NYHA class, left ventricular outflow tract gradients (LVOTg) at rest and Valsalva, and left ventricular ejection fraction (LVEF) in patients with symptomatic obstructive HCM treated with mavacamten for up to 72 weeks. Results: Mavacamten was initiated in 172 patients across 4 US centers (UCSF, Mayo Arizona, Stanford, and Atlantic Health System/Morristown Medical Center). Baseline characteristics included: 56% female, mean age 64 (standard deviation ±13) years, 47% NYHA class III, mean resting LVOTg of 47 mmHg and mean Valsalva LVOTg of 89 mmHg, and 23% non-White. Comorbidities included hypertension (56%) and atrial fibrillation (25%) at baseline (Table). Patients experienced a notable early response to mavacamten in resting and Valsalva gradients by week 4, which was sustained through week 72 (Figure A). No patients were NYHA class III at week 72, compared to 47% at baseline (Figure B). Mean LVEF did not change substantially between baseline and week 72. No patients experienced an LVEF of <40% and 2% experienced an LVEF of <50%. Conclusions: This is the largest observational study to date demonstrating the effectiveness and safety of mavacamten with substantial sustained reductions in resting and Valsalva LVOTg, and progressive improvements in NYHA class without considerable changes in mean LVEF up to 72 weeks.